Usted buscó: immunodefiä‹jenza (Maltés - Inglés)

jenza akuta renali.
investigations very common:

pazjenti b’ insuffi jenza epatika
patients with hepatic insufficiency no dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency.

ċ jenza l-fażi ta’ żvilupp u validazzjoni.
ic ts of interest in the development and validation phase.

e ƒ ċ jenza akbar tippermetti li jkun hemmanqas spejjeż.
greater efficiency allows for lower costs.

tesavel ma iex studjat f’ pazjenti b’ insuffi jenza epatika.
tesavel has not been studied in patients with severe hepatic insufficiency.

esperjenza minn studji klini i b’ tesavel f’ pazjenti b’ insuffi jenza renali moderata jew qawwija hi limitata.
clinical study experience with tesavel in patients with moderate or severe renal insufficiency is limited.

l-esper-jenza tagħna tagħti rwol partikolari lill-ue fit-trawwim tal-integrazzjoni reġjonali.
our experience gives the eu a particular role in fostering regional integration.

l-esper-jenza ta’ galileo tissuġġerixxi li l-approċċ għal dawn l-intrapriżi ġodda għandujkunippjanatsewwa urealistiku.
experience of galileo suggeststhattheapproachtothesenewventuresshouldbe well planned andrealistic.

15 pazjenti b’ insuffi jenza renali ija tal- krejatinina [crcl] ≥50 ml/ min,, m’ hemmx g al pazjenti b’ insuffi jenza renali afifa (tne b onn bidla fid- do a ta ’ tesavel.
14 patients with renal insufficiency for patients with mild renal insufficiency (creatinine clearance [crcl] ≥ 50 ml/ min), no dosage adjustment for tesavel is required.